As part of The Next 100 Days guide, which identifies the key IP issues that businesses should be focussing on right now, we look at the topic of Crown Use and how it might impact on innovators in the wake of the pandemic.
Emmy Hunt and Edwina Fitzhugh summarise the most recent High Court decision. Sky v SkyKick, C-371/18, 29th April 2020.
The Court of Justice of the EU has handed down its judgment in Royalty Pharma (C-650/17) on the interpretation of Art. 3(a) of the EU’s Regulation on Supplementary Protection Certificates.
As businesses around the world face difficult operational challenges on multiple fronts, this guide is designed to help you to align your shifting commercial goals with an effective approach to intellectual property.
Genentech applied for an SPC in February 2007 to cover the compound Ranibizumab. Ranibizumab is a key constituent of the drug Lucentis which treats “wet” macular degeneration - an eye condition, which causes age-related vision loss.
These are unprecedented times for all businesses, with pressure to adapt to a constantly evolving ‘new normal’. With challenges to address on multiple fronts, here are four areas of focus to help ensure your intellectual property approach is aligned to your immediate business priorities.